Drugmaker AbbVie plans to construct a $195 million facility near its headquarters in North Chicago to manufacture active pharmaceutical ingredients, The Chicago Tribune reported Aug. 12.
Construction is set to begin in the fall and is expected to be completed by 2027. The expansion adds to AbbVie’s large footprint in the state of Illinois, where it employs over 11,000 individuals across offices and manufacturing sites.
The new investment is also part of the state’s “Economic Development for a Growing Economy” program, which offers tax incentives to companies investing $100 million or more in Illinois.
The announcement follows similar moves by other large drugmakers, including AstraZeneca, Johnson & Johnson and Eli Lilly, to boost domestic manufacturing.
